Literature DB >> 2415085

The influence of Norakin on the reproduction of influenza A and B viruses.

H Heider, S Markushin, C Schroeder, Y Ghendon.   

Abstract

The action of the anticholinergic drug Norakin (triperiden) on the reproduction of influenza virus A and B strains was studied. In cell culture, primary transcription of influenza A/FPV/Weybridge and of influenza B/Japan/73 is strongly inhibited by Norakin (20 micrograms/ml). When present simultaneously, Norakin and rimantadine exert an additive effect. Rimantadine-resistant mutants of influenza A exhibit a definite, though limited, cross-resistance to Norakin, and vice versa. The results indicate that Norakin blocks early stages of the infectious cycle and that the modes of antiviral action of Norakin and rimantadine are not identical.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415085     DOI: 10.1007/bf01309832

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  16 in total

1.  SEROLOGICAL EVIDENCE FOR PREVENTION OF INFLUENZAL INFECTION IN VOLUNTEERS BY AN ANTI-INFLUENZAL DRUG ADAMANTANAMINE HYDROCHLORIDE.

Authors:  G G JACKSON; R L MULDOON; L W AKERS
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1963

2.  Transcription of the influenza virus genome.

Authors:  A J Hay; B Lomniczi; A R Bellamy; J J Skehel
Journal:  Virology       Date:  1977-12       Impact factor: 3.616

3.  Temperature-sensitive mutants of reovirus. I. Patterns of gene expression by mutants of groups C, D, and E.

Authors:  Y Ito; W K Joklik
Journal:  Virology       Date:  1972-10       Impact factor: 3.616

4.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

5.  [Study of formation of amantidine and rimantidine resistant variants of influenza A2 subtype virus].

Authors:  V I Il'enko
Journal:  Vopr Virusol       Date:  1975 Mar-Apr

6.  ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE).

Authors:  W L DAVIES; R R GRUNERT; R F HAFF; J W MCGAHEN; E M NEUMAYER; M PAULSHOCK; J C WATTS; T R WOOD; E C HERMANN; C E HOFFMANN
Journal:  Science       Date:  1964-05-15       Impact factor: 47.728

7.  Antiviral activity of Norakin (triperiden) and related anticholinergic antiparkinsonism drugs.

Authors:  H W Presber; C Schroeder; B Hegenscheid; H Heider; J Reefschläger; H A Rosenthal
Journal:  Acta Virol       Date:  1984-11       Impact factor: 1.162

8.  On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride.

Authors:  J J Skehel; A J Hay; J A Armstrong
Journal:  J Gen Virol       Date:  1978-01       Impact factor: 3.891

9.  Amantadine-resistance as a genetic marker for influenza viruses.

Authors:  G Appleyard
Journal:  J Gen Virol       Date:  1977-08       Impact factor: 3.891

10.  Inhibition of influenza virus uncoating by rimantadine hydrochloride.

Authors:  W C Koff; V Knight
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

View more
  6 in total

1.  Neutral red-labeled influenza virus loses photosensitivity during absorption to host cells but not to erythrocytes.

Authors:  C Schroeder; H Heider; H J Eggers
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

2.  Mutations in the hemagglutinin gene associated with influenza virus resistance to norakin.

Authors:  S Prösch; H Heider; C Schroeder; D H Krüger
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

3.  Relation between drug resistance and antigenicity among norakin-resistant mutants of influenza A (fowl plague) virus.

Authors:  A I Klimov; S G Markushin; S Prösch; V P Ginzburg; H Heider; A M Heider; C Schröeder; R G Webster
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

Review 4.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 5.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

Review 6.  Influenza virus entry.

Authors:  Ming Luo
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.